Latest Developments
03 February 2011
A5 Laboratories has received approval letter for it’s containment level 2 facility.
MONTREAL, QUEBEC–(Marketwire – 02/03/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the office of Biohazard and Containment Safety
01 February 2011
A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product
MONTREAL, QUEBEC–(Marketwire – 02/01/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner.
Investors
A5 Laboratories Investment Information
Trading under the symbol AFLB.OB, A5 Laboratories stock is available on the OTC Bulletin Board. For additional Investment info see the following:Sec Filings
Free trading issued: 20,500,000
Restricted issued: 25,000,000
Total issued: 45,500,000
Available to issue: 54,500,000
Authorized Shares: 100,000,000 common/100,000,000 preferred
CUSIP #: 00830E 105
Year end: 09/30
Incorporation date: June 21, 2006
Incorporated in: Nevada
Officers: Mr. Richard Azani, CEO